Blockchain Registration Transaction Record

BetterLife Pharma Taps Former Cybin CEO to Advance Non-Hallucinogenic LSD Treatment

BetterLife Pharma appoints former Cybin CEO Doug Drysdale to advance BETR-001 for cluster headache & migraine treatment using non-hallucinogenic LSD derivative technology.

This development matters because it represents a significant advancement in neurological treatment options that could revolutionize how we approach debilitating conditions like cluster headaches and migraines. Cluster headaches are considered one of the most painful conditions known to medicine, often called 'suicide headaches' due to their severity, and current treatments provide limited relief for many sufferers. The non-hallucinogenic nature of BETR-001 removes the stigma and regulatory barriers associated with traditional psychedelic compounds, potentially making effective treatment more accessible. For the millions worldwide who suffer from treatment-resistant migraines and cluster headaches, this could mean a new class of effective medications that don't carry the psychoactive effects that have limited broader acceptance of psychedelic-based therapies. The appointment of an experienced pharmaceutical executive like Drysdale suggests serious commercial potential and could accelerate the development timeline for bringing this innovative treatment to patients in need.